BNT329 + CA19-9-targeting monoclonal antibody for endometrial neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 22 Sep 2025: Trial registered, NCT07186842
  2. 18 Nov 2025: Trial started, NCT07186842

The trials

NCT07186842: A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

State
Under way
Phase
Phase 1 and Phase 2
People
245 planned
Started
18 Nov 2025
Primary completion
May 2030
Arms
Dose Escalation: Part C
Results
None posted
  1. 22 Sep 2025: Trial registered
  2. 18 Nov 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.